FDA approves ViiV's Juluca dolutegravir/rilpivirine for HIV-1 infection

FDA approved Juluca dolutegravir/rilpivirine from ViiV Healthcare Ltd. (Brentford, U.K.) to treat HIV-1 infection. The agency said Juluca is the first single-tablet regimen that consists of only 2 drugs that is approved for HIV maintenance. Current standard HIV treatments include ≥3 drugs.

Juluca is indicated for patients with HIV-1 infection who are virally suppressed on a stable regimen for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca. ViiV did not respond to an inquiry regarding Juluca’s price or launch plans...